A practical approach to the detection of prognostically significant genomic aberrations in multiple myeloma

Journal of Molecular Diagnostics

Volumn 7, Issue 5, 2005, Pages 560-565

  Chen, Zhong ^a   Issa, Bonnie ^a   Huang, Shiang ^b   Aston, Emily ^a   Xu, Jia ^a   Yu, Margaret ^a   Brothman, Arthur R ^a   Glenn, Martha ^a  

^a UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

^b HUAZHONG UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

IMMUNOGLOBULIN; IMMUNOGLOBULIN HEAVY CHAIN; PROTEIN P53; RETINOBLASTOMA PROTEIN; SYNDECAN 1;

ADULT; AGED; ARTICLE; B LYMPHOCYTE; CELL SELECTION; CHROMOSOME ABERRATION; CONTROLLED STUDY; CYTOGENETICS; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; HUMAN; HUMAN CELL; INTERPHASE; MAJOR CLINICAL STUDY; MALE; MOLECULAR PROBE; MULTIPLE MYELOMA; PLASMA CELL; PROGNOSIS; RELIABILITY;

EID: 27744509798     PISSN: 15251578     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1525-1578(10)60588-0     Document Type: Article

References (33)

1. Kaufmann H, Urbauer E, Ackermann J, Huber H, Drach J: Advances in the biology and therapeutic management of multiple myeloma. Ann Hematol 2001, 80:445-451
2. Bataille R, Boccadoro M, Klein B, Durie B, Pileri A: C-reactive protein and beta-2 microglobulin produce a simple and powerful myeloma staging system. Blood 1992, 80:733-737
3. Greipp PR, Lust JA, O'Fallon WM, Katzmann A, Witzig TE, Kyle RA: Plasma cell labeling index and beta 2-microglobulin predict survival independent of thymidine kinase and C-reactive protein in multiple myeloma. Blood 1993, 81:3382-3387
4. Konigsberg R, Zojer N, Ackermann J, Kromer E, Kittler H, Fritz E, Kaufmann H, Nosslinger T, Riedl L, Gisslinger H, Jager U, Simonitsch I, Heinz R, Ludwig H, Huber H, Drach J: Predictive role of interphase cytogenetics for survival of patients with multiple myeloma. J Clin Oncol 2000, 18:804-812
5. Fonseca R, Harrington D, Oken MM, Dewald GW, Bailey RJ, Van Wier SA, Henderson KJ, Blood EA, Rajkumar SV, Kay NE, Van Ness B, Greipp PR: Biological and prognostic significance of interphase fluorescence in situ hybridization detection of chromosome 13 abnormalities (delta-13) in multiple myeloma: an eastern cooperative oncology group study. Cancer Res 2002, 62:715-720
6. Zojer N, Konigsberg R, Ackermann J, Fritz E, Dallinger S, Kromer E, Kaufmann H, Riedl L, Gisslinger H, Schreiber S, Heinz R, Ludwig H, Huber H, Drach J: Deletion of 13q14 remains an independent adverse prognostic variable in multiple myeloma despite its frequent detection by interphase fluorescence in situ hybridization. Blood 2000, 95:1925-1930
7. Fonseca R, Barlogie B, Bataille R, Bastard C, Bergsagel PL, Chesi M, Davies FE, Drach J, Greipp PR, Kirsch IR, Kuehl WM, Hernandez JM, Minvielle S, Pilarski LM, Shaughnessy JD Jr, Stewart AK, Avet-Loiseau H: Genetics and cytogenetics of multiple myeloma: a workshop report. Cancer Res 2004, 64:1546-1558
8. Dewald GW, Kyle RA, Hicks GA, Greipp PR: The clinical significance of cytogenetic studies in 100 patients with multiple myeloma, plasma cell leukemia, or amyloidosis. Blood 1985, 66:380-390
9. Smadja NV, Fruchart C, Isnard F, Louvet C, Dutel JL, Cheron N, Grange MJ, Monconduit M, Bastard C: Chromosomal analysis in multiple myeloma: cytogenetic evidence of two different diseases. Leukemia 1998, 12:960-969
10. Lai JL, Zandecki M, Mary JY, Bernardi F, Izydorczyk V, Flactif M, Morel P, Jouet JP, Bauters F, Facon T: Improved cytogenetics in multiple myeloma: a study of 151 patients including 117 patients at diagnosis. Blood 1995, 85:2490-2497
11. Debes-Marun CS, Dewald GW, Bryant S, Picken E, Santana-Davila R, Gonzalez-Paz N, Winkler JM, Kyle RA, Gertz MA, Witzig TE, Dispenzieri A, Lacy MQ, Rajkumar SV, Lust JA, Greipp PR, Fonseca R: Chromosome abnormalities clustering and its implications for pathogenesis and prognosis in myeloma. Leukemia 2003, 17:427-436
12. Fonseca R, Blood E, Rue M, Harrington D, Oken MM, Kyle RA, Dewald GW, Van Ness B, Van Wier SA, Henderson KJ, Bailey RJ, Greipp PR: Clinical and biologic implications of recurrent genomic aberrations in myeloma. Blood 2003, 101:4569-4575
13. Morgan R, Chen Z, Richkind K, Roherty S, Velasco J, Sandberg AA: PHA/IL2: an efficient mitogen cocktail for cytogenetic studies of non-Hodgkin lymphoma and chronic lymphocytic leukemia. Cancer Genet Cytogenet 1999, 109:134-137
14. Wijdenes J, Vooijs WC, Clement C, Post J, Morard F, Vita N, Laurent P, Sun RX, Klein B, Dore JM: A plasmocyte selective monoclonal antibody (B-B4) recognizes syndecan-1. Br J Haematol 1996, 94:318-323
15. Pellat-Deceunynck C, Bataille R, Robillard N, Harousseau JL, Rapp MJ, Juge-Morineau N, Wijdenes J, Amiot M: Expression of CD28 and CD40 in human myeloma cells: a comparative study with normal plasma cells. Blood 1994, 84:2597-2603
16. Schneider U, van Lessen A, Huhn D, Serke S: Two subsets of peripheral blood plasma cells defined by differential expression of CD45 antigen. Br J Haematol 1997, 97:56-64
17. Ahmann GJ, Jalal SM, Juneau AL, Christensen ER, Hanson CA, Dewald GW, Greipp PR: A novel three-color, clone-specific fluorescence in situ hybridization procedure for monoclonal gammopathies. Cancer Genet Cytogenet 1998, 101:7-11
18. Bernfield M, Kokenyesi R, Kato M, Hinkes MT, Spring J, Gallo RL, Lose EJ: Biology of the syndecans: a family of transmembrane heparan sulfate proteoglycans. Annu Rev Cell Biol 1992, 8:365-393
19. Couchman JR, Woods A: Syndecans, signaling, and cell adhesion. J Cell Biochem 1996, 61:578-584
20. Lin P, Owens R, Tricot G, Wilson CS: Flow cytometric immunophenotypic analysis of 306 cases of multiple myeloma. Am J Clin Pathol 2004, 121:482-488
21. Avet-Loiseau H, Facon T, Daviet A, Godon C, Rapp MJ, Harousseau JL, Grosbois B, Bataille R: 14q32 translocations and monosomy 13 observed in monoclonal gammopathy of undetermined significance delineate a multistep process for the oncogenesis of multiple myeloma. Intergroupe Francophone du Myelome. Cancer Res 1999, 59:4546-4550
22. Avet-Loiseau H, Facon T, Grosbois B, Magrangeas F, Rapp MJ, Harousseau JL, Minvielle S, Bataille R; Intergroupe Francophone du Myelome. Oncogenesis of multiple myeloma: 14q32 and 13q chromosomal abnormalities are not randomly distributed, but correlate with natural history, immunological features, and clinical presentation. Blood 2002; 99:2185-2191
23. Fiserova A, Hajek R, Holubova V, Buchler T, Sobotka J, Kovarova R, Musilova R, Bourkova L, Bulikova A, Mareschova I, Janackova Z, Vanova P, Kuglik P, Vorlicek J, Penka M: Detection of 13q abnormalities in multiple myeloma using immunomagnetically selected plasma cells. Neoplasma 2002, 49:300-306
24. Zandecki M, Lai JL, Facon T: Multiple myeloma: almost all patients are cytogenetically abnormal. Br J Haematol 1996, 94:217-227
25. Drach J, Schuster J, Nowotny H, Angerler J, Rosenthal F, Fiegl M, Rothermundt C, Gsur A, Jager U, Heinz R, Lechner K, Ludwig H, Huber H: Multiple myeloma: high incidence of chromosomal aneuploidy as detected by interphase fluorescence in situ hybridization. Cancer Res 1995, 55:3854-3859
26. Shaughnessy J, Tian E, Sawyer J, Bumm K, Landes R, Badros A, Morris C, Tricot G, Epstein J, Barlogie B: High incidence of chromosome 13 deletion in multiple myeloma detected by multiprobe interphase FISH. Blood 2000, 96:1505-1511
27. Juneau AL, Kaehler M, Christensen ER, Schad CR, Zinsmeister AR, Lust J, Hanson C, Dewald GW: Detection of RB1 deletions by fluorescence in situ hybridization in malignant hematologic disorders. Cancer Genet Cytogenet 1998, 103:117-123
28. Facon T, Avet-Loiseau H, Guillerm G, Moreau P, Genevieve F, Zandecki M, Lai JL, Leleu X, Jouet JP, Bauters F, Harousseau JL, Bataille R, Mary JY: Chromosome 13 abnormalities identified by FISH analysis and serum beta2-microglobulin produce a powerful myeloma staging system for patients receiving high-dose therapy. Blood 2001, 97:1566-1571
29. Drach J, Ackermann J, Fritz E, Kromer E, Schuster R, Gisslinger H, DeSantis M, Zojer N, Fiegl M, Roka S, Schuster J, Heinz R, Ludwig H, Huber H: Presence of a p53 gene deletion in patients with multiple myeloma predicts for short survival after conventional-dose chemotherapy. Blood 1998, 92:802-809
30. Nishida K, Tamura A, Nakazawa N, Ueda Y, Abe T, Matsuda F, Kashima K, Taniwaki M: The Ig heavy chain gene is frequently involved in chromosomal translocations in multiple myeloma and plasma cell leukemia as detected by in situ hybridization. Blood 1997, 90:526-534
31. Avet-Loiseau H, Li JY, Facon T, Brigaudeau C, Morineau N, Maloisel F, Rapp MJ, Talmant P, Trimoreau F, Jaccard A, Harousseau JL, Bataille R: High incidence of translocations t(11;14)(q13;q32) and t(4;14)(p16;q32) in patients with plasma cell malignancies. Cancer Res 1998, 58:5640-5645
32. Avet-Loiseau H, Brigaudeau C, Morineau N, Talmant P, Lai JL, Daviet A, Li JY, Praloran V, Rapp MJ, Harousseau JL, Facon T, Bataille R: High incidence of cryptic translocations involving the Ig heavy chain gene in multiple myeloma, as shown by fluorescence in situ hybridization. Genes Chromosomes Cancer 1999, 24:9-15
33. Sawyer JR, Waldron JA, Jagannath S, Barlogie B: Cytogenetic findings in 200 patients with multiple myeloma. Cancer Genet Cytogenet 1995, 82:41-49